The former Kate Middleton was diagnosed with cancer early in 2024, and much speculation about the state of her health has followed. Catherine, Princess of Wales, has since shared that she ...

Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...

Atara Biotherapeutics said on Tuesday the U.S. health regulator has placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket ...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...

Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report), reducing the price target ...

Heartburn and acid reflux are common during chemotherapy ("chemo"), caused by cancer drugs subsequently attacking cells of the stomach and esophagus (feeding tube). Symptoms can flare immediately ...

Atara Biotherapeutics Inc. shares tumbled over 35% on Thursday afternoon, reaching their lowest intraday levels since mid-October. The sharp decline followed the announcement that the U.S. Food and ...

Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...